Galectin-3 in patients undergoing ablation of atrial fibrillation

Clémenty, Nicolas; Piver, Éric; Benhenda, Nazih; Bernard, Anne; Pierre, Bertrand; Siméon, Edouard; Fauchier, Laurent; Pagès, Jean‐Christophe; Babuty, Dominique

doi:10.1016/j.ijcme.2014.10.003

Cited by 15 publications

(19 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among the 38 full‐text articles assessed for eligibility, ten were excluded for the following reasons: One study lacked a control group; one study population was heart failure; four studies lacked available data for further analysis; and four reported duplicate data from studies that later published as full text . Finally, 28 studies involving 10 830 patients were included in our meta‐analysis, with their baseline characteristics shown in Tables and .…”

Section: Resultsmentioning

confidence: 99%

“…Furthermore, we showed that higher galectin‐3 levels were associated with a 45% increase in the odds of developing AF (odds ratio [OR] = 1.45, 95% CI: 1.15, 1.83, Z = 3.11, P = .002) (Figure B). Six studies compared galectin‐3 levels between paroxysmal AF and persistent AF patients . The pooled analysis showed that galectin‐3 levels were significantly higher in the persistent AF group (MD = −0.94 ng/mL, 95% CI: −1.85, −0.03, Z = 2.04, P = .04) (Figure C).…”

Section: Resultsmentioning

confidence: 99%

“…Six studies compared galectin-3 levels between paroxysmal AF and persistent AF patients. 24,35,37,41,48,50 The pooled analysis showed that galectin-3 levels were significantly higher in the persistent AF group (MD = −0.94 ng/mL, 95% CI: −1.85, −0.03, Z = 2.04, P = .04) ( Figure 2C).…”

Section: Re Sultsmentioning

confidence: 97%

See 2 more Smart Citations

Galectin‐3 and risk of atrial fibrillation: A systematic review and meta‐analysis

Gong

Cheung

Wang

et al. 2020

Clinical Laboratory Analysis

View full text Add to dashboard Cite

Background Galectin‐3 is an inflammatory marker that is raised in myocardial fibrosis and inflammation. Recent studies have explored its role in predicting atrial fibrillation (AF) outcomes. The aim of this systematic review and meta‐analysis is to examine the association between serum concentration of galectin‐3 and AF. Methods PubMed, EMBASE, and the Cochrane Database were searched. A total of 280 studies were identified, of which 28 studies involving 10 830 patients were included in our meta‐analysis. Results Galectin‐3 is present at higher concentrations in patients with AF than those in sinus rhythm (mean difference [MD] = −0.68 ng/mL, 95% CI: −0.92, −0.44, Z = 5.61, P < .00001). Galectin‐3 levels were significantly higher in the persistent AF than in the paroxysmal AF group (MD = −0.94 ng/mL, 95% CI: −1.85, −0.03, Z = 2.04, P = .04). Higher galectin‐3 levels were associated with a 45% increase in the odds of developing AF (odds ratio [OR] = 1.45, 95% CI: 1.15, 1.83, Z = 3.11, P = .002) and risk of AF recurrence (hazard ratio [HR] =1.17, 95% CI: 1.06, 1.29, Z = 3.12, P = .002). Conclusions Our meta‐analysis found that galectin‐3 is significantly higher in patients with persistent AF than in those with paroxysmal AF, and can predict both AF development and recurrence after treatment.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Galectin‐3 and risk of atrial fibrillation: A systematic review and meta‐analysis

Gong

Cheung

Wang

et al. 2020

Clinical Laboratory Analysis

View full text Add to dashboard Cite

show abstract

“…In a recent study, higher circulating galectin‐3 concentrations were found to be related with increased risk of AF development over the subsequent 10 years in age‐ and sex‐adjusted analyses . In several studies, higher levels of serum galectin‐3 were detected in AF patients …”

Section: Introductionmentioning

confidence: 95%

The Association of Serum Galectin‐3 Levels with Atrial Electrical and Structural Remodeling

Yalçın

Gürses

Koçyiğit

et al. 2015

Cardiovasc electrophysiol

View full text Add to dashboard Cite

show abstract

“…Moreover, atrial remodeling and fibrosis play important roles in persistent AF (3,4) . Recent studies have shown a significant association between left atrial (LA) global longitudinal strain (GLS) and AF progression, with significantly decreased LA GLS in patients with paroxysmal AF (4,5) . In longterm AF, fibrosis is an important factor causing mechanical dysfunction (2) .…”

Section: Introductionmentioning

confidence: 99%

Galectin-3 in Middle-Aged Patients with First Episode of Non-valvular Atrial Fibrillation: a Speckle-tracking Study

Kılıçgedik¹,

Efe²,

Gürbüz³

et al. 2017

Kosuyolu Heart Journal

View full text Add to dashboard Cite

Introduction: Recent studies have shown a significant association between left atrial (LA) global longitudinal strain (GLS) and the progression of atrial fibrillation (AF) with significantly decreased LA GLS in patients with paroxysmal AF. Significantly higher levels of serum galectin-3 have also been found in patients with non-valvular AF. This study aimed to examine the relationship of the early stage of atrial fibrosis and reduced atrial deformation with serum galectin-3 concentration in middle-aged patients with a first episode of nonvalvular AF. Patients and Methods:This study prospectively enrolled 34 patients who were admitted to our emergency department and required either a medical or electrical cardioversion due to the first episode of AF, without any structural or coronary heart disease and with normal LA size. Additionally, 31 control subjects were also enrolled. The diameter, volume, and mechanical function of LA, including strain (S) and strain rate (SR), and serum galectin-3 levels were measured. Results:The average age was 48.5 ± 10.4 years. Galectin-3 values were not significantly different between the AF and control groups (r= 0.42; p= 0.51) and were found to correlate inversely with peak negative SR on apical four chamber (r= −0.31, p= 0.02) and two chamber (r= −0.25, p= 0.04) views. In comparison to the control group, the AF group had significantly lower values of peak systolic S on four chamber view (p= 0.037), peak late diastolic S (p= 0.04), peak positive SR on apical four-chamber view (p= 0.04), and peak late negative SR on apical four chamber (p= 0.03) and two-chamber (p= 0.02) views. Conclusion:Middle-aged patients with the first episode of AF and normal LA sizes had reduced LA reservoir and active atrial functions. Although beginning signs of LA functional remodeling were shown on S and SR imaging, these were not completely reflected by serum galectin-3 levels.Key Words: Atrial fibrillation; strain; strain rate; galectin-3 İlk Atak Non-valvular Atrial Fibrilasyonlu Orta Yaşlı Hastalarda Galectin-3 ÖZET Giriş: Biz bu çalışmada ilk atak non-valvular atriyal fibrilasyon (AF)'lu orta yaşlı hasta grubunda serum galectin konsantrasyonu ile AF erken evresi arasındaki ilişkiyi araştırdık. Hastalar ve Yöntem:Bu çalışmaya acil servisimize ilk atak AF ile başvuran, medikal ya da elektriki kardiyoversiyon yapılmış, yapısal ya da koroner kalp hastalığı olmayan normal LA boyuta sahip 34 hasta ve 31 kontrol hastası prospektif olarak dahil edildi. Ekokardiyografik bulgular kayıt altına alındı ve serum galectin düzeyleri ekokardiyografi öncesi alınan kan örneklerinden ölçüldü. Bulgular:Hastaların ortalama yaşı 48.5 ± 10.4 yıldı. Galectin değerleri arasında AF ve kontrol grubu arasında anlamlı fark saptanmadı (r= 0.42 ; p= 0.51) ve apikal dört boşluk (r= -0.31, p= 0.02) ve iki boşluk görüntü-den (r= -0.25 , p= 0.04) pik negatif SR ile negatif korele bulundu. Kontrol grubu ile karşılaştırıldığında, AF grubunda dört boşluk görüntüden pik sistolik strain (p= 0.037), pik geç diastolik strain (p= 0.0...

show abstract

Galectin-3 in patients undergoing ablation of atrial fibrillation

Cited by 15 publications

References 25 publications

Galectin‐3 and risk of atrial fibrillation: A systematic review and meta‐analysis

Galectin‐3 and risk of atrial fibrillation: A systematic review and meta‐analysis

The Association of Serum Galectin‐3 Levels with Atrial Electrical and Structural Remodeling

Galectin-3 in Middle-Aged Patients with First Episode of Non-valvular Atrial Fibrillation: a Speckle-tracking Study

Contact Info

Product

Resources

About